文献速递眼底病与葡萄膜炎小儿眼科与斜弱视

在当代瑞典队列中验证DIGIROP模型及决策支持工具对早产儿视网膜病变治疗的预测

Validation of DIGIROP models and decision support tool for prediction of treatment for retinopathy of prematurity on a contemporary Swedish cohort.
PubMed 文献 · Br J Ophthalmol · 2022-03-11

研究基于瑞典国家早产儿视网膜病变登记(2018-2019)及两个地区(2020)共1082例胎龄24至<31周婴儿,验证DIGIROP-Birth与DIGIROP-Screen模型及决策支持工具。DIGIROP-Birth的AUC为0.93(95%CI 0.90-0.95),DIGIROP-Screen的AUC为0.93至0.97;出生时应用工具的特异度49.9%(95%CI 46.7-53.0),敏感度96.5%(95%CI 87.9-99.6)。结论认为两模型预测能力高,出生时约50%婴儿可预测为低风险并可能免于筛查。

要点

  • DIGIROP-Birth预测需治疗ROP的AUC为0.93(95%CI 0.90-0.95)。
  • DIGIROP-Screen的AUC范围为0.93至0.97。
  • 出生时应用决策工具:特异度49.9%(95%CI 46.7-53.0),敏感度96.5%(95%CI 87.9-99.6)。

核心结论

  • DIGIROP-Birth和DIGIROP-Screen在当代瑞典队列中显示出高预测能力。
  • 出生时,胎龄24至<31周的婴儿中约50%被预测为严重ROP低风险,可能免于ROP筛查检查。
  • 所有常规筛查的治疗婴儿(因严重疾病临床指征筛查者除外)均被正确标记为需要ROP筛查。

研究设计与样本

  • 数据来自瑞典国家ROP登记(2018-2019)及两个瑞典地区(2020),共纳入1082例胎龄24至<31周的婴儿。
  • 预测因子为出生胎龄、性别、标准化出生体重及首次ROP体征出现时的年龄。
  • 结局为ROP治疗;描述了敏感度、特异度及受试者工作特征曲线下面积(AUC)及95%CI。

主要发现

  • DIGIROP-Birth的AUC为0.93(95%CI 0.90至0.95)。
  • DIGIROP-Screen的AUC范围为0.93至0.97。
  • 出生时应用工具的特异度为49.9%(95%CI 46.7至53.0),敏感度为96.5%(95%CI 87.9至99.6)。
  • DIGIROP-Screen的累积特异度范围为50.0%至78.7%。
  • 1例Beckwith-Wiedemann综合征婴儿符合ROP治疗标准且无遗漏/不完整检查,被错误标记为不需要筛查。

关键数值与推荐

  • DIGIROP-Birth的AUC为0.93(95%CI 0.90至0.95)。
  • DIGIROP-Screen的AUC为0.93至0.97。
  • 出生时应用工具:特异度49.9%(95%CI 46.7至53.0),敏感度96.5%(95%CI 87.9至99.6)。
  • DIGIROP-Screen累积特异度为50.0%至78.7%。

临床怎么用

  • 原作者认为,出生时约50%的胎龄24至<31周婴儿可被预测为严重ROP低风险,并可能免于ROP筛查检查;所有常规筛查的治疗婴儿(因严重疾病临床指征筛查者除外)均被正确标记为需要筛查。

局限性

  • 1例Beckwith-Wiedemann综合征婴儿符合ROP治疗标准且无遗漏/不完整检查,被错误标记为不需要筛查。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND/AIMS: Retinopathy of prematurity (ROP) is currently diagnosed through repeated eye examinations to find the low percentage of infants that fulfil treatment criteria to reduce vision loss. A prediction model for severe ROP requiring treatment that might sensitively and specifically identify infants that develop severe ROP, DIGIROP-Birth, was developed using birth characteristics. DIGIROP-Screen additionally incorporates first signs of ROP in different models over time. The aim was to validate DIGIROP-Birth, DIGIROP-Screen and their decision support tool on a contemporary Swedish cohort. METHODS: Data were retrieved from the Swedish national registry for ROP (2018-2019) and two Swedish regions (2020), including 1082 infants born at gestational age (GA) 24 to <31 weeks. The predictors were GA at birth, sex, standardised birth weight and age at the first sign of ROP. The outcome was ROP treatment. Sensitivity, specificity and area under the receiver operating characteristic curve (AUC) with 95% CI were described. RESULTS: For DIGIROP-Birth, the AUC was 0.93 (95% CI 0.90 to 0.95); for DIGIROP-Screen, it ranged between 0.93 and 0.97. The specificity was 49.9% (95% CI 46.7 to 53.0) and the sensitivity was 96.5% (95% CI 87.9 to 99.6) for the tool applied at birth. For DIGIROP-Screen, the cumulative specificity ranged between 50.0% and 78.7%. One infant with Beckwith-Wiedemann syndrome who fulfilled criteria for ROP treatment and had no missed/incomplete examinations was incorrectly flagged as not needing screening. CONCLUSIONS: DIGIROP-Birth and DIGIROP-Screen showed high predictive ability in a contemporary Swedish cohort. At birth, 50% of the infants born at 24 to <31 weeks of gestation were predicted to have low risk of severe ROP and could potentially be released from ROP screening examinations. All routinely screened treated infants, excluding those screened for clinical indications of severe illness, were correctly flagged as needing ROP screening.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Pivodic A, E H Smith L, Hård AL, et al. Validation of DIGIROP models and decision support tool for prediction of treatment for retinopathy of prematurity on a contemporary Swedish cohort. Br J Ophthalmol. 2022. PMID: 35277395. doi:10.1136/bjophthalmol-2021-320738

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。